Sage Therapeutics to Present at American Epilepsy Society 70th Annual Meeting
December 01 2016 - 4:30PM
Business Wire
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage
biopharmaceutical company developing novel medicines to treat
life-altering central nervous system (CNS) disorders, today
announced upcoming presentations at the American Epilepsy
Society (AES) 70th Annual Meeting, taking place December 2-6,
2016 in Houston, TX. Members of the company’s medical
affairs team will be accessible at booth number 918.
Below is the schedule for the presentations and a Sage-sponsored
scientific exhibit:
Date: Saturday, December 3, 2016Poster Presentation
Time: 12:00 p.m. – 6:00 p.m. CTLocation: Hall A3/Level
3, George R. Brown Convention CenterPoster Number:
1.261Title: SAGE-217, a next generation neuroactive
steroid positive allosteric modulator of synaptic and
extra-synaptic GABAA receptors, is active against audiogenic
seizures in Fmr1 knockout mice
Date: Sunday, December 4, 2016Poster Presentation
Time: 10:00 a.m. – 4:00 p.m. CTLocation: Hall
A3/Level 3, George R. Brown Convention CenterPoster Number:
2.187Title: SGE-516, a next generation neuroactive
steroid, reduces status epilepticus (SE) after a 20 or 40-minute
treatment delay in a rat model of soman intoxication
Date: Sunday, December 4, 2016Poster Presentation
Time: 10:00 a.m. – 4:00 p.m. CTLocation: Hall A3/Level
3, George R. Brown Convention CenterPoster Number:
2.185Title: SAGE-689, a potent and selective next
generation neuroactive steroid, reduces electrographic seizure
activity in a rat model of pharmacoresistant status epilepticus
while phenytoin does not
Date: Sunday, December 4, 2016Sage Sponsored
Scientific Exhibit Time: 2 p.m. – 5 p.m. CTLocation:
Room 360 ADTitle: Neuroactive Steroids in the Treatment of
GABAA-Related Disorders.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical
company committed to developing novel medicines to transform the
lives of patients with life-altering central nervous system (CNS)
disorders. Sage has a portfolio of novel product candidates
targeting critical CNS receptor systems, GABA and NMDA. Sage's lead
program, SAGE-547, is in Phase 3 clinical development for
super-refractory status epilepticus, a rare and severe seizure
disorder, and is being developed for postpartum depression. Sage is
developing its next generation modulators, including SAGE-217 and
SAGE-718, with a focus on acute and chronic CNS disorders. For more
information, please visit www.sagerx.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161201006314/en/
Investor Contact:Sage TherapeuticsPaul Cox,
617-299-8377paul.cox@sagerx.comorMedia Contact:Suda
Communications LLCMaureen L. Suda,
585-387-9248maureen.suda@sagerx.com
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Apr 2023 to Apr 2024